HeraMED Limited announce that it has signed an MOU with the Gold Coast Hospital to trial the HeraCARE platform as its new standard of care for their Women Newborn and Children Services (WNCS). Initially, a controlled trial of the HeraCARE platform will be undertaken for up to 90 pregnancies for a period of six to nine months with an objective to evaluate clinical usability, patient satisfaction, value for money and economic analysis. Concurrently, HeraMED will work with Gold Coast Health to undertake a Clinical implementation study to assess several use cases including acceptance, cost effective analysis and clinical outcomes.

On successful completion of the trial, subject to a proper market scan, value for money assessment and results of clinical outcomes, GCHHS intends to order additional licences.